Delta-Fly Pharma (TYO:4598) said it will begin a phase 2/3 trial for DFP-17729 combined with TS-1 in patients with advanced pancreatic cancer after receiving approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), according to a Monday filing on the Tokyo Stock Exchange.
The study, to be conducted at 15 clinical sites in Japan, will measure overall survival as the primary endpoint. If DFP-17729 with TS-1 shows superior efficacy to TS-1 alone, the drug could receive new drug approval from the PMDA.
TS-1, developed by Taiho Pharmaceutical, is used to treat several cancers, including pancreatic cancer.
Price (JPY): $590.00, Change: $+9.0, Percent Change: +1.55%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。